Zilbrysq (Zilucoplan Sodium) Patent Expiration, LOE Window & CMS Spending

Zilbrysq (Zilucoplan Sodium) by Ucb: FDA Orange Book core substance LOE 2035-06-12, 0 AB generics, $40.8M 2024 CMS Part D & Medicaid spend, and $41,300 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUcb
FDA Application & PathwayN216834 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-06-12
Last Listed Patent or Exclusivity Date2035-06-12
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$40.8M
2024 Medicare Part D Spend$37.1M
2024 Medicaid Spend$3.6M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($41,300 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.